• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Effect of combination therapy of gene therapy with a Del1 and antibody-drug

Research Project

Project/Area Number 18K09800
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 57060:Surgical dentistry-related
Research InstitutionNihon University

Principal Investigator

KITANO Hisataka  日本大学, 医学部, 准教授 (50424726)

Project Period (FY) 2018-04-01 – 2021-03-31
Project Status Completed (Fiscal Year 2020)
Budget Amount *help
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Keywords癌 / 遺伝子治療 / ゲノム
Outline of Final Research Achievements

In a study of the 2018, E3C1 in Del1 was found to affect the change of cell membrane properties in vitro. In a 2019 study, treated by cisplatin (CDDP) + E3C1 inhibited tumor growth in explanted tumor in nude mice. Furthermore, treated by CDDP + E3C1 improved the life prognosis of mice. In a 2020 Study revealed that the therapeutic effect of CDDP+E3C1 is a change in the number and morphology of tumor blood vessels. These results suggest that gene therapy with CDDP+E3C1 for mouse transplanted tumors affects the properties of endothelial cells of tumor blood vessels and cell membranes of cancer cells. As a result, it was thought that the growth of mouse explanted tumors was inhibited. Furthermore, it was suggested that the prognosis of mice was prolonged.

Academic Significance and Societal Importance of the Research Achievements

現在、世界中でがん治療に対する多剤併用療法は数多く行われており著しい進歩を遂げている。さらに併用療法は、治療に対する耐性を抑制する効果も期待されており、今後化学療法の主流になっていくと予想される。そして、今回の研究でシスプラチン(CDDP)+E3C1 による遺伝子治療がin vivoの実験系でマウスの生命予後を副作用の発現を伴わず改善できたことは、がん治療に新しい可能性を提案できるのではないかと考えている。さらには、今回の研究結果ががん遺伝子治療に留まらず、多種多様な遺伝子治療に貢献できればと考えている。

Report

(4 results)
  • 2020 Annual Research Report   Final Research Report ( PDF )
  • 2019 Research-status Report
  • 2018 Research-status Report
  • Research Products

    (3 results)

All 2021 2018

All Journal Article (3 results) (of which Peer Reviewed: 3 results,  Open Access: 3 results)

  • [Journal Article] Combination Cancer Therapy of a Del1 Fragment and Cisplatin Enhanced Therapeutic Efficiency In Vivo.2021

    • Author(s)
      Hisataka Kitano, Yoh Masaoka, Atsushi Mamiya, Yusuke Fujiwara, Toshio Miki, Chiaki Hidai.
    • Journal Title

      In Vivo

      Volume: 35 Issue: 2 Pages: 779-791

    • DOI

      10.21873/invivo.12318

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Nonviral Gene Therapy for Cancer: A Review2018

    • Author(s)
      Chiaki Hidai, Hisataka Kitano
    • Journal Title

      Diseases

      Volume: 6 Issue: 3 Pages: 1-12

    • DOI

      10.3390/diseases6030057

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Efficient cancer gene therapy with a Del1 fragment administered by hypodermic injection in a mouse explanted tumor model2018

    • Author(s)
      Hisataka Kitano, Tomomi Ishikawa, Eri Tamura, Shinichiro Kokubun, Chiaki Hidai
    • Journal Title

      Translational Cancer Researc

      Volume: 7 Issue: 3 Pages: 686-694

    • DOI

      10.21037/tcr.2018.05.45

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access

URL: 

Published: 2018-04-23   Modified: 2022-01-27  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi